Molecular mechanism and application of translationally controlled tumor protein in tumor targeting therapy

doi:10.3760/cma.j.issn.1673-422X.2015.10.009

Abstract

Abstract: Translationally controlled tumor protein (TCTP) is a small protein highly conserved in a variety of eukaryotic species. TCTP is overexpressed in various tumor cells and has been implicated in the regulation of cellular processes including apoptosis, DNA repair and drug resistance. By reviewing the recent progress of TCTP research, TCTP is becoming an important regulator of DNA repair and a new molecular target for tumor therapy.

Key words: DNA damage, Drug resistance, neoplasm, Translationally controlled tumor protein

Han Yujing, Li Yilan, Ning Xuelian, Sun Huiying, Zhou Chunshui.. Molecular mechanism and application of translationally controlled tumor protein in tumor targeting therapy[J]. Journal of International Oncology, 2015, 42(10): 753-755.

References

［1］ Lu YJ, Lu G, Shi DZ, et al. Bioinformatic analysis for structure and function of TCTP from Spirometra mansoni［J］. Asian Pac J Trop Med, 2013, 6(9): 709-712. ［2］ NaganoIto M, Ichikawa S. Biological effects of Mammalian translationally controlled tumor protein (TCTP) on cell death, proliferation, and tumorigenesis［J］. Biochem Res Int, 2012, 2012: 204960. ［3］ Ma YP, Zhu WL. Cytoplasmic and nuclear localization of TCTP in normal and cancer cells［J］. Biochem Res Int, 2012, 2012: 871728. ［4］ Cucchi U, Gianellini LM, De Ponti A, et al. Phosphorylation of TCTP as a marker for pololike kinase1 activity in vivo［J］. Anticancer Res, 2010, 30(12): 4973-4985. ［5］ Yarm FR. Plk phosphorylation regulates the microtubulestabilizing protein TCTP［J］. Mol Cell Biol, 2002, 22(17): 6209-6221. ［6］ Zhang J, de Toledo SM, Pandey BN, et al. Role of the translationally controlled tumor protein in DNA damage sensing and repair［J］. Proc Natl Acad Sci USA, 2012, 109(16): E926-E933. ［7］ Hong ST, Choi KM. TCTP directly regulates ATM activity to control genome stability and organ development in drosophila melanogaster［J］. Nat Commun, 2013, 4: 2986. ［8］ van Soest RJ, de Morree ES, Shen L, et al. Initial biopsy gleason score as a predictive marker for survival benefit in patients with castrationresistant prostate cancer treated with docetaxel: data from the TAX327 study［J］. Eur Urol, 2013, 66(2):330-336. ［9］ Deng SS, Xing TY, Zhou HY, et al. Comparative proteome analysis of breast cancer and adjacent normal breast tissues in human［J］. Genomics Proteomics Bioinformatics, 2006, 4(3): 165-172. ［10］ Kim JE, Koo KH, Kim YH, et al. Identification of potential lung cancer biomarkers using an in vitro carcinogenesis model［J］. Exp Mol Med, 2008, 40(6): 709-720. ［11］ Chung S, Kim M, Choi W, et al. Expression of translationally controlled tumor protein mRNA in human colon cancer［J］. Cancer Lett, 2000, 156(2): 185-190. ［12］ Zhu WL, Cheng HX, Han N, et al. Messenger RNA expression of translationally controlled tumor protein (TCTP) in liver regeneration and cancer［J］. Anticancer Res, 2008, 28(3A): 1575-1580. ［13］ Bull VH, Fargestad EM, Strozynski M, et al. Temporal proteome profiling of taxolinduced mitotic arrest and apoptosis［J］. Electrophoresis, 2010, 31(11): 1873-1885. ［14］ Ge F, Zhang L, Tao SC, et al. Quantitative proteomic analysis of tumor reversion in multiple myeloma cells［J］. J Proteome Res, 2011, 10(2): 845-855. ［15］ Lucibello M, Adanti S, Antelmi E, et al. PhosphoTCTP as a therapeutic target of dihydroartemisinin for aggressive breast cancer cells［J］. Oncotarget, 2015, 6(7): 5275-5291. ［16］ Miao X, Chen YB, Xu SL, et al. TCTP overexpression is associated with the development and progression of glioma［J］. Tumour Biol, 2013, 34(6): 3357-3361. ［17］ Li F, Zhang D, Fujise K. Characterization of fortilin, a novel antiapoptotic protein［J］. J Biol Chem, 2001, 276(50): 47542-47549. ［18］ Graidist P, Phongdara A, Fujise K. Antiapoptotic protein partners fortilin and MCL1 independently protect cells from 5-fluorouracilinduced cytotoxicity［J］. J Biol Chem, 2004, 279(39): 40868-40875. ［19］ Fujita T, Felix K, Pinkaew D, et al. Human fortilin is a molecular target of dihydroartemisinin［J］. FEBS Lett, 2008, 582(7): 1055-1060. ［20］ Liu LK, Wu HF, Guo ZR, et al. Targeted efficacy of dihydroartemisinin for translationally controlled protein expression in a lung cancer model［J］. Asian Pac J Cancer Prev, 2014, 15(6): 2511-2515. ［21］ Baylot V, Katsogiannou M, Andrieu C, et al. Targeting TCTP as a new therapeutic strategy in castrationresistant prostate cancer［J］. Mol Ther, 2012, 20(12): 2244-2256. ［22］ Ma Q, Geng Y, Xu W, et al. The role of translationally controlled tumor protein in tumor growth and metastasis of colon adenocarcinoma cells［J］. J Proteome Res, 2010, 9(1): 40-49. ［23］ Tuynder M, Fiucci G, Prieur S, et al. Translationally controlled tumor protein is a target of tumor reversion［J］. Proc Natl Acad Sci USA, 2004, 101(43): 15364-15369. ［24］ Amson R, Pece S, Lespagnol A, et al. Reciprocal repression between P53 and TCTP［J］. Nat Med, 2011, 18(1): 91-99.

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou. Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer [J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Yuan Jian, Huang Yanhua. Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer [J]. Journal of International Oncology, 2024, 51(6): 338-343.
[4]	Chen Hongjian, Zhang Suqing. Study on the relationship between serum miR-24-3p， H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients [J]. Journal of International Oncology, 2024, 51(6): 344-349.
[5]	Guo Zehao, Zhang Junwang. Role of PFDN and its subunits in tumorigenesis and tumor development [J]. Journal of International Oncology, 2024, 51(6): 350-353.
[6]	Zhang Baihong, Yue Hongyun. Advances in anti-tumor drugs with new mechanisms of action [J]. Journal of International Oncology, 2024, 51(6): 354-358.
[7]	Xu Fenglin, Wu Gang. Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma [J]. Journal of International Oncology, 2024, 51(6): 359-363.
[8]	Wang Ying, Liu Nan, Guo Bing. Advances of antibody-drug conjugate in the therapy of metastatic breast cancer [J]. Journal of International Oncology, 2024, 51(6): 364-369.
[9]	Zhang Rui, Chu Yanliu. Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota [J]. Journal of International Oncology, 2024, 51(6): 370-375.
[10]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[11]	Liu Jing, Liu Qin, Huang Mei. Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm [J]. Journal of International Oncology, 2024, 51(5): 267-273.
[12]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin. Study on the clinical relationship between inflammatory burden index and gastric cancer [J]. Journal of International Oncology, 2024, 51(5): 274-279.
[13]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao. Effect of cancer nodules on liver metastases after radical resection of colorectal cancer [J]. Journal of International Oncology, 2024, 51(5): 280-285.
[14]	Zhang Ningning, Yang Zhe, Tan Limei, Li Zhenning, Wang Di, Wei Yongzhi. Diagnostic value of cervical cell DNA ploidy analysis combined with B7-H4 and PKCδ for cervical cancer [J]. Journal of International Oncology, 2024, 51(5): 286-291.
[15]	Fu Yi, Ma Chenying, Zhang Lu, Zhou Juying. Research progress of habitat analysis in radiomics of malignant tumors [J]. Journal of International Oncology, 2024, 51(5): 292-297.